SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections

Other recent posts

Abstract

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

View Link

Abstract

A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors

View Link

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.